Abstract: This invention is directed to the crystal structure of Estrogen Receptor-? (ER-?) complexed with genistein, and to the use of this structure in rational drug design methods to identify agents that may interact with active sites of ER-?, which may be useful as novel chemotherapeutic agents.
Type:
Application
Filed:
April 13, 2007
Publication date:
September 18, 2008
Applicant:
Genetics Institute, LLC.
Inventors:
William S. Somers, Zhang-Bao Xu, Tatos N. Akopian, Chu-Lai Hsiao, Rayomand Unwalla
Abstract: Polynucleotides encoding the MU-1 hematopoietin receptor superfamily chain and fragments thereof are disclosed. MU-1 proteins and methods for their production are also disclosed.
Abstract: This invention provides a chimeric DNA molecule comprising a sequence encoding a chemokine polypeptide covalently attached to a heterologous polypeptide, the encoded chimeric polypeptide, and uses thereof.
Type:
Grant
Filed:
July 7, 2003
Date of Patent:
July 8, 2008
Assignee:
Genetics Institute, LLC
Inventors:
Stephen H. Herrmann, Stephen L. Swanberg
Abstract: Purified cartilage and/or bone inductive proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and/or cartilage defects and in wound healing and related tissue repair.
Type:
Grant
Filed:
October 6, 1994
Date of Patent:
May 27, 2008
Assignee:
Genetics Institute, LLC
Inventors:
Rodney M. Hewick, Jack H. Wang, John M. Wozney, Anthony J. Celeste
Abstract: The invention provides isolated nucleic acids molecules, designated PD-L2 nucleic acid molecules, which encode novel B7-related molecules which are ligands for PD-1. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PD-L2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PD-L2 gene has been introduced or disrupted. The invention further provides isolated PD-L2 polypeptides, fusion proteins, antigenic peptides and anti-PD-L2 antibodies. The invention still further provides methods for promoting or inhibiting the interaction between PD-L2 and PD-1. Diagnostic and treatment methods utilizing compositions of the invention are also provided.
Type:
Application
Filed:
June 20, 2007
Publication date:
May 22, 2008
Applicants:
Dana-Farber Cancer Institute, Inc., Genetics Institute LLC
Inventors:
Gordon Freeman, Irene Chernova, Tatyana Chernova, Nelly Malenkovich, Clive R. Wood
Abstract: Compositions of proteins with tendon/ligament-like tissue inducing activity are disclosed. The compositions are useful in the treatment of tendinitis and tendon or ligament defects and in related tissue repair.
Type:
Grant
Filed:
June 17, 2005
Date of Patent:
April 29, 2008
Assignees:
Genetics Institute, LLC., President and Fellows of Harvard College
Inventors:
Anthony J. Celeste, John M. Wozney, Vicki A. Rosen, Neil M. Wolfman, Gerald H. Thomsen, Douglas A. Melton
Abstract: The invention relates to humanized anti-B7-2 and anti-B7-1 antibodies, wherein each comprise a variable region of non-human origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.
Abstract: Methods and compositions are provided for the treatment of articular cartilage defects and disease involving the combination of tissue, such as osteochondral grafts, with active growth factor. The active growth factor is preferably a composition containing at least one bone morphogenetic protein and a suitable carrier. The method results in the regeneration and/or functional repair of articular cartilage tissue.
Type:
Grant
Filed:
February 18, 2004
Date of Patent:
January 29, 2008
Assignee:
Genetics Institute, LLC
Inventors:
Renwen Zhang, Diane Peluso, Elisabeth Morris
Abstract: Novel human GIL-19/AE289 protein is disclosed which shows a high degree of homology to interleukin-10 (IL-10). Polynucleotides encoding such protein are also enclosed.
Type:
Grant
Filed:
April 28, 2000
Date of Patent:
December 11, 2007
Assignee:
Genetics Institute, LLC
Inventors:
Kenneth Jacobs, Lynette Fouser, Vikki Spaulding, Dejun Xuan
Abstract: Purified BMP-2 and BMP-4 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair.
Type:
Grant
Filed:
March 9, 2001
Date of Patent:
November 27, 2007
Assignee:
Genetics Institute, LLC
Inventors:
Elizabeth A. Wang, John M. Wozney, Vicki A. Rosen
Abstract: Inhibitors of IL-22 are disclosed as well as pharmaceutical compositions and methods of using same. The inhibitors include IL-22 antibodies and are useful for treating inflammatory disorders.
Type:
Grant
Filed:
September 27, 2002
Date of Patent:
October 9, 2007
Assignee:
Genetics Institute, LLC
Inventors:
Kenneth Jacobs, Debra D. Pittman, Lynette Fouser, Vikki Spaulding, Dejun Xuan
Abstract: The invention identifies PD-1 as a receptor for B7-4. B7-4 can inhibit immune cell activation upon binding to an inhibitory receptor on an immune cell. Accordingly, the invention provides agents for modulating PD-1, B7-4, and the interaction between B7-4 and PD-1 in order to modulate a costimulatory or an inhibitory signal in a immune cell resulting in modulation of the immune response.
Type:
Application
Filed:
August 31, 2006
Publication date:
August 30, 2007
Applicants:
Genetics Institute, LLC, Dana-Farber Cancer Institute, Inc.
Abstract: Methods and compositions for treating a wide range of inflammatory diseases and disorders, and for inhibiting selectin-mediated binding by administering a mocarhagin protein, or fragments thereof with mocarhagin protein activity are provided. The mocarhagin protein may be administered alone, or in combination with a cytokine, lymphokine, or hematopoietic factor.
Type:
Grant
Filed:
February 25, 2005
Date of Patent:
August 7, 2007
Assignee:
Genetics Institute, LLC
Inventors:
Amechand Boodhoo, Jasbir S. Seehra, Gray Shaw, Dianne Sako
Abstract: This invention is directed to the crystal structure of Estrogen Receptor-? (ER-?) complexed with genistein, and to the use of this structure in rational drug design methods to identify agents that may interact with active sites of ER-?, which may be useful as novel chemotherapeutic agents.
Type:
Grant
Filed:
July 11, 2001
Date of Patent:
June 26, 2007
Assignee:
Genetics Institute, LLC.
Inventors:
William S. Somers, Zhang-Bao Xu, Tatos N. Akopian, Chu-Lai Hsiao, Rayomand Unwalla
Abstract: Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.
Type:
Grant
Filed:
January 4, 2005
Date of Patent:
June 19, 2007
Assignees:
The United States as represented by the Secretary of the Navy, The Regents of the University of Michigan, Genetics Institute, LLC
Inventors:
Carl H. June, Craig B. Thompson, Gary J. Nabel, Gary S. Gray, Paul D. Rennert
Abstract: The present invention provides a process for dissociating Fc-containing molecules from complexes of Protein A/Fc-containing molecules or mixtures containing Fc-containing molecules and Protein A. The association, e.g., by hydrophobic interactions, between the Fc-containing molecules and Protein A can be reduced or inhibited by raising the pH of dissociation. The pH of dissociation can be raised by addition of agents capable of inhibiting hydrophobic interactions, including buffers containing arginine and/or ethylene glycol, to the mixture, either prior to adding the mixture to the column chromatography substrate, after adding the mixture to the column chromatography substrate, or both prior to and after adding the mixture to the column chromatography substrate.
Type:
Grant
Filed:
June 5, 2002
Date of Patent:
May 29, 2007
Assignee:
Genetics Institute, LLC
Inventors:
Jonathan L. Coffman, William B. Foster, Shujun Sun
Abstract: Polynucleotides encoding the human IL-11 receptor and fragments thereof are disclosed. IL-11 receptor proteins, methods for their production, inhibitors of binding of human IL-11 and its receptor and methods for their identification are also disclosed.
Abstract: Purified BMP-2 and BMP-4 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair.
Type:
Grant
Filed:
March 27, 2003
Date of Patent:
May 15, 2007
Assignee:
Genetics Institute, LLC
Inventors:
Elizabeth Wang, John M. Wozney, Vicki A. Rosen
Abstract: The invention provides methods for downmodulating an immune response comprising contacting immune cells from a subject with at least one agent that binds to at least one B7 molecule in combination with a Rapamycin compound.
Abstract: Methods and compositions for modulating interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using agonists or antagonists of IL-21 or IL-21 receptor (“IL-21R” or “MU-1”), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo, e.g., for treating or preventing immune cell-associated pathologies (e.g., pathologies associated with aberrant activity of one or more of mature T cells (mature CD8+, mature CD4+ T cells), mature NK cells, B cells, macrophages and megakaryocytes, including transplant rejection and autoimmune disorders). IL-21/IL-21R agonists can be used by themselves or in combination with an antigen, e.g., as an adjuvant (e.g., a vaccine adjuvant), to up-regulate an immune response in vivo, e.g., for example, for use in treating cancer and infectious disorders.
Type:
Grant
Filed:
October 4, 2002
Date of Patent:
April 3, 2007
Assignee:
Genetics Institute, LLC
Inventors:
Laura Carter, Beatriz Carreno, Leslie D. Lowe, Matthew J. Whitters, Kyri Dunussi, Mary Collins, Margery Ma, Deborah A. Young, JoAnn S. Witek, Glenn Larsen, Marion T. Kasaian, Debra D. Donaldson, Michelle Unger